Related Experiment Video

Updated: Apr 13, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Li Ren Kong1, Kian Ngiap Chua1, Wen Jing Sim2

  • 1Cancer Science Institute of Singapore, National University of Singapore, Singapore.

Molecular Cancer Therapeutics
|May 6, 2015
PubMed

Insights

Targeting the MAPK-ERK pathway can overcome cisplatin resistance in squamous cell carcinoma (SCC). Inhibiting MEK/ERK enhances chemotherapy effectiveness and tolerability, improving treatment outcomes for SCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Platinum-based chemotherapy is standard for squamous cell carcinoma (SCC), but resistance limits treatment efficacy.
  • Genomic studies have not yet identified key pathways for targeted SCC treatment strategies.
  • Understanding resistance mechanisms is crucial for improving SCC patient outcomes.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying cisplatin resistance in SCC.
  • To identify potential therapeutic targets to overcome chemoresistance in SCC.
  • To evaluate the clinical relevance of identified pathways in head and neck SCC.

Main Methods:

  • Comparative analysis of gene and protein expression in cisplatin-sensitive versus -resistant SCC cells.
  • Investigation of the Son of Sevenless (SOS)-MAPK-ERK pathway's role in cisplatin resistance.
  • In vitro and in vivo studies assessing the efficacy of MEK/ERK inhibition combined with cisplatin.

Main Results:

  • Upregulation and activation of the MAPK-ERK pathway were identified in cisplatin-resistant SCC cells.
  • Elevated p-ERK expression correlated with reduced disease-free survival in head and neck SCC patients.
  • Inhibition of MEK/ERK, but not EGFR or RAF, resensitized SCC cells to cisplatin and showed therapeutic potential.

Conclusions:

  • The SOS-MAPK-ERK pathway plays a critical role in mediating cisplatin resistance in SCC.
  • Targeting MEK/ERK signaling is a promising strategy to enhance cisplatin efficacy in SCC.
  • This approach may improve treatment responses and survival for patients with advanced SCC.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.3K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.6K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.4K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K